- Although MannKind's ( NASDAQ: MNKD ) Q2 2022 net loss narrowed 18% to $29M compared to the prior-year period, that wasn't enough to beat consensus estimates on the bottom line .
- Revenue of ~$18.9M, around a 19% year-over-year decline, however, was a beat.
- MannKind ( MNKD ) was negatively impacted in the quarter by a ~17% increase in total expenses to ~$39.3M.
- Gross profit for inhaled insulin product Afrezza in the quarter was $7.3M, a 31% increase from Q2 2021.
- MannKind ( MNKD ) ended the quarter with $35.5M in cash and cash equivalents, a ~71% decline from Dec. 31, 2021.
- Seeking Alpha's Quant Rating views MannKind ( MNKD ) as a buy.
For further details see:
MannKind down 2% after Q2 2022 bottom line miss; however, net loss narrowed